arrow
S

Simin Aysel Florescu

dr victor babes clinical hospital of infectious and tropical diseases
H指数:19
被引数:1,386

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Factors associated with SARS-CoV-2 infection among healthcare workers: a European multicentre cohort study, May 2021–April 2024

与医疗保健工作者SARS-CoV-2感染相关的因素:一项欧洲多中心队列研究,2021年5月至2024年4月

2026-08-070
OA
Emergence and Comparative Analysis of Candidozyma auris Versus Candida spp. Candidemia in a Romanian Tertiary Hospital: A 7-Year Study on Resistance, Mortality and Independent Prognostic Factors

罗马尼亚一家三级医院中新型念珠菌属与念珠菌属血流感染的涌现和比较分析:一项关于耐药性、死亡率和独立预后因素的7年研究

2026-07-020
OA
Genomic and Clinical Profile of Hypervirulent Klebsiella pneumoniae (ST23-K1) Liver Abscesses: Experience with Patients at a Romanian University Hospital

高毒力肺炎克雷伯菌(ST23-K1)肝脓肿的基因组学和临床特征:罗马尼亚大学医院患者经验

2026-02-200
OA
Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023)

第二剂加强针COVID-19疫苗在预防实验室确诊SARS-CoV-2感染方面的相对有效性:医疗保健工作者VEBIS HCW VE队列研究(2022年10月1日至2023年5月2日)

VACCINE
IF3.5
2025-01-010
OAAI
A Possible Tool for Guiding Therapeutic Approaches to Urinary Infections with Klebsiella pneumoniae: Analyzing a Dataset from a Romanian Tertiary Hospital

指导肺炎克雷伯菌尿路感染治疗方法的可能工具: 分析罗马尼亚三级医院的数据集

2024-12-030
OA
Incidence of SARS-CoV-2 Infection Among European Healthcare Workers and Effectiveness of the First Booster COVID-19 Vaccine, VEBIS HCW Observational Cohort Study, May 2021-May 2023

欧洲卫生保健工作者中SARS-CoV-2感染的发生率和第一个加强新型冠状病毒肺炎疫苗的有效性,VEBIS HCW观察性队列研究,2021年5月-2023年5月

2024-11-192
OAAI
Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24
2024-10-310
OAAI
Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)

碳青霉烯类耐药肠杆菌引起的感染的可归因死亡率: 一项前瞻性、多国病例-对照匹配队列研究 (EURECA) 的结果

2024-02-0111
OA
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
2022-08-0816
OAAI